Your Messages Inbox
Your Article Summary
See Latest ArticlesAbbotts XIENCE V Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS Liberte in Investigator-Initiated COMPARE Trial
Abbott, 09/24/09
Late–breaking data presented from the COMPARE trial demonstrated that Abbott's market–leading XIENCE V Everolimus Eluting Coronary Stent System demonstrated significantly better outcomes in key safety and efficacy measures compared to the TAXUS Liberte Paclitaxel–Eluting Coronary Stent System.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Article Search
Sponsor